ACHEMA in Short
It’s the last day at ACHEMA! With a few more hours left before the show draws to a close, here’s a brief summary of the key trends observed during the week.
It’s the last day at ACHEMA! With a few more hours left before the show draws to a close, here’s a brief summary of the key trends observed during the week.
Gone are the days of the blockbusters. The pharmaceutical industry is definitely moving towards personalized medicines. As therapies become more targeted to a specific population, batch sizes are getting smaller. And pharmaceutical manufacturers are consequently looking for flexibility in their production lines, such as short changover times, easy cleaning of equipment and machinery, and process automation to name a few. The industry is beginning to recognize the advantages of modular production plants. The personalized medicines era is also driving up the number of highly potent drug products, resulting in a demand for containment solutions and isolators.
In bioprocesssing, single use has no doubt made significant in roads, more so upstream than downstream. Single use suppliers now have a good understanding of their materials, hence the risk of extractables and leachables isn’t so much of an issue as before. Of course, challenges still exist, such as the lack of standardization and guidance from regulators.
Not only is pharmaceutical manufacturing is advancing but there is significant progress observed in bioprocessing as well. It is all because of the innovators who are constantly finding solutions to common problems. ACHEMA has indeed provided a platform for the process industry to showcase its technologies. So as we say goodbye to the show, and as exhibitors pack up and go their separate ways, here’s to all the engineers and scientists who have made a difference in the industry.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.
